A. Garfall

发表

Teclistamab in Relapsed or Refractory Multiple Myeloma.

A. Krishnan, J. Goldberg, H. Nahi, 2022, The New England journal of medicine.

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

R. Verona, M. Samtani, C. Uhlar, 2023, Targeted Oncology.

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

A. Krishnan, J. Goldberg, J. Infante, 2021, The Lancet.

Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.

A. Chari, B. Hilder, J. Tolbert, 2024, Clinical lymphoma, myeloma & leukemia.